Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease

Abstract

For most patients with chronic fibrosing ILDs, the 150 mg nintedanib BID dose provides exposure levels associated with a therapeutic effect close to the maximum nintedanib effect independent of disease condition or baseline demographics.